Member Info for amones

Didn’t the CEO mention, few months ago, about “some exciting news to the investors in 2021”?
Is it just incidental that the sp has stopped dropping further (at least, at the time of typing this!)?

If the motive behind regularly selling small to medium size chunks over the last 2 months was indeed to drop the share price and subsequently to accommodate an easy private takeover. Possibly, rationale behind keeping the stocks listed on the unregulated AIM market. I sincerely hope the company is not thinking on that line.

Last paragraph on page 57 of company’s presentation published yesterday says “Continue to monitor market conditions for listings on other stock exchanges such as Hong Kong & Shanghai”. Monitoring the conditions continues to be the company’s aim for year 2021!

122 pages of clear, detailed and colourful presentation. After glancing through the information about the products, research and manufacturing facilities, scientific and marketing teams, revenues and further prospects in the presentation, the question we all trying to find an answer is , ‘why this dismal share price and market valuation?’

Its a deliberate act to lower market capitalization. As one poster on advfn has opined, the company might go privete. But, whet about the big fund managers who have made investments of $ 300 million in the recent months? Has anyone from these funds made any noise?

Very good analysis, tacly.
You are spot on about the reasons behind lowering share price. Every investor, big or small, who has put their money into this company has done so, after doing due research about the management, its assets, research facilities, openings it has made in the USA, drugs in the pipeline and future potentials. When all such prospects have been intact and progressing well (as per company’s news releases so far), why should any investor be inclined to sell at a loss? Hence, the drip feeding of small selling orders is, very likely, deliberately done so as to keep the shares low. But, for what reasons? Is it to scare away all private investors? Does it help the company to quote significantly lower initial listing price in HK/Shanghai?
Btw, what’s on the agenda in today’s investors conference? Are we going to see the repeat act of selected financial analysts turning into onco-pharmaceutical experts asking questions about the role of particular chemical molecules of different drug candidates waiting in the pipeline? Shall we expect to hear /see some decent (and honest) discussion about Asian listing/s, migration to the main LSE market and collaborations with major pharmas etc.,?

ADRs performance yesterday was a decent one. SP on NYSE stayed over $30 for most part of the day with 195k shares exchanging hands. Is it sign of any forthcoming good news? We have been waiting for US approval for surufatinib/ Listing of Hutchmed stocks on HKSE , in addition to few other prospective news for quite sometime. One little tick is what we have been waiting.

Market and investors opinion would be changed if the company could do two things;
1. Moving out of the unregulated AIM market to the better regulated main LSE market so as to allow investments from major fund managers (and also investors from China to invest using ‘LSE- Shanghai stock market link’, created 2 years ago)
and,
2. Listing on Hong Kong and STAR markets.

Advantages of doing so has been discussed several times by many on this message board, over the past couple of years, especially the former option.

As per recent statement from the CEO, HK/STAR listing might be accomplished in the coming months. In addition, much anticipated approvals for Sulanda in the USA and China will be helpful to boost the sp. Keeping the fingers crossed ( as has been doing for the past few years!).

Tacly, do you think the company is eyeing only on couple of chunks of $100 millions from GA like funds ( but, not interested in few hundred millions from Asian investors)? And, why would GA like funds invest chunks of 100 millions, if they can not see any prospect of growth of their investments until 2024?

Yesterday, 1.26 million ADRs were traded (? mostly sales) at NYSE with the share price sliding significantly. Is it a sign of investors loosing interest and patience? Are the investors saying ‘we have waited long enough’?

Management wanted to confirm ‘successful commercialisation’ before going ahead with HK/STAR markets listing. Recently declared results have shown such success with growing sales of Fruquintinib and Sulanda. CEO has repeatedly mentioned about the ‘imminent’ Asian listing/s. Let us hope the same will happen very soon.

Davey, has this information (as well as the Trinity data) been posted on stockwitt? That could be of some help to the American investors following that website. Lately, have noticed messages related to another company ( ?hcmc) are posted there.

Great pharmaceutical company with excellent research and development wing, good management, nice looking pipeline, and majority owned by Hutchison group. Reasonably decent set of year end results. But, the market doesn’t like the lack of information about something which has been expected for a while (?listing on asian market), ADRs price drops to $28+. ( from $ 37+ Two weeks ago). Lets be ready to see sub £4 tomorrow on AIM. Sad and disappointing, indeed.

CEO, please get sort it out.

In fact, ended the day with a ‘healthy’ rise of 7.4% :)
However, what’s the source for the rumour about ‘probable RNS’?
Yet another statement about ‘imminent Asian listing/s’? Or, more definitive news?
288k ADRs were traded yesterday. Fingers crossed.

Ended at $36.52 last night. Wonder if ADRs ever traded at these prices? Volume traded 258k.
Nice profit for the two big funds who invested $100 millions recently.
Thanks to Jatw and Davey for keeping followers of this bb informed.

Thanks Davey. That’s a very good piece of information.

A major fund is investing $ 100 million. Its a big show of confidence in this company. But, both markets behaving as if nothing has happened!
Waiting for the approval for Surufatinib to be announced. Research and Clinical data published has been encouraging. Fingers crossed until then.

London-Shanghai link isn’t useful to HCM at present as it is listed on AIM.
However, UK investors holding AIM listed shares, will be benefitted if HCM can manage to keep its London listing after listing at HK (+/- Shanghai). But, is it possible to have listings on 3 (or ? 4 ) markets, one of those being LSE, at the same time?

When GA’s investment was announced, few months ago, share price went up. But, following today’s news of investment by CPP, share price actually went down by few pence. Shouldn’t this show of confidence by a major Canadian fund holder be a welcoming news?

It will be very nice for UK based investors, if it’s possible to have concurrent listings at London/ NYSE/HK /Shanghai.
Is it allowed??

Following the main political headline news from last night, let us hope that the coming days to be much more favourable for HCM to do business in the USA.

We can expect a much better response from the market once the much anticipated approval for Surufatinib by the Chinese authorities comes through by the year end.
Until then, it is a good chance for believers of this company to buy.

(No recommendations intended. Do your own research)

Typical for this stock. No news means dropping sp. Overall negative stock market sentiment due to Covid is an added disadvantage. People selling seem to forget the expected big news about Surufatinib.